Literature DB >> 27823876

Optimal Volume of Administration of Intranasal Midazolam in Children: A Randomized Clinical Trial.

Daniel S Tsze1, Maria Ieni2, Daniel B Fenster2, John Babineau2, Joshua Kriger3, Bruce Levin3, Peter S Dayan2.   

Abstract

STUDY
OBJECTIVE: The optimal intranasal volume of administration for achieving timely and effective sedation in children is unclear. We aimed to compare clinical outcomes relevant to procedural sedation associated with using escalating volumes of administration to administer intranasal midazolam.
METHODS: We conducted a randomized, single-blinded, 3-arm, superiority clinical trial. Children aged 1 to 7 years and undergoing laceration repair requiring 0.5 mg/kg intranasal midazolam (5 mg/mL) were block-randomized to receive midazolam using 1 of 3 volumes of administration: 0.2, 0.5, or 1 mL. Procedures were videotaped, with outcome assessors blinded to volume of administration. Primary outcome was time to onset of minimal sedation (ie, score of 1 on the University of Michigan Sedation Scale). Secondary outcomes included procedural distress, time to procedure start, deepest level of sedation achieved, adverse events, and clinician and caregiver satisfaction.
RESULTS: Ninety-nine children were enrolled; 96 were analyzed for the primary outcome and secondary outcomes, except for the outcome of procedural distress, for which only 90 were analyzed. Time to onset of minimal sedation for each escalating volume of administration was 4.7 minutes (95% confidence interval [CI] 3.8 to 5.4 minutes), 4.3 minutes (95% CI 3.9 to 4.9 minutes), and 5.2 minutes (95% CI 4.6 to 7.0 minutes), respectively. There were no differences in secondary outcomes except for clinician satisfaction with ease of administration: fewer clinicians were satisfied when using a volume of administration of 0.2 mL.
CONCLUSION: There was a slightly shorter time to onset of minimal sedation when a volume of administration of 0.5 mL was used compared with 1 mL, but all 3 volumes of administration produced comparable clinical outcomes. Fewer clinicians were satisfied with ease of administration with a volume of administration of 0.2 mL.
Copyright © 2016 American College of Emergency Physicians. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27823876      PMCID: PMC5406242          DOI: 10.1016/j.annemergmed.2016.08.450

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  35 in total

Review 1.  Permeability issues in nasal drug delivery.

Authors:  Priyanka Arora; Shringi Sharma; Sanjay Garg
Journal:  Drug Discov Today       Date:  2002-09-15       Impact factor: 7.851

Review 2.  Intranasal medication delivery for children: a brief review and update.

Authors:  Timothy R Wolfe; Darren A Braude
Journal:  Pediatrics       Date:  2010-08-09       Impact factor: 7.124

Review 3.  A review of the clinical pharmacokinetics of opioids, benzodiazepines, and antimigraine drugs delivered intranasally.

Authors:  Nicole M L Veldhorst-Janssen; Audrey A A Fiddelers; Paul-Hugo M van der Kuy; Cees Neef; Marco A E Marcus
Journal:  Clin Ther       Date:  2009-12       Impact factor: 3.393

Review 4.  Intranasal drug delivery: how, why and what for?

Authors:  Anaísa Pires; Ana Fortuna; Gilberto Alves; Amílcar Falcão
Journal:  J Pharm Pharm Sci       Date:  2009       Impact factor: 2.327

5.  Efficacy and safety of nitrous oxide in alleviating pain and anxiety during painful procedures.

Authors:  S A Kanagasundaram; L J Lane; B P Cavalletto; J P Keneally; M G Cooper
Journal:  Arch Dis Child       Date:  2001-06       Impact factor: 3.791

6.  The safety and efficacy of using a concentrated intranasal midazolam formulation for paediatric dental sedation.

Authors:  Michael Wood
Journal:  SAAD Dig       Date:  2011-01

Review 7.  Nasal administration of opioids for pain management in adults.

Authors:  O Dale; R Hjortkjaer; E D Kharasch
Journal:  Acta Anaesthesiol Scand       Date:  2002-08       Impact factor: 2.105

8.  Early pharmacokinetics of nasal fentanyl: is there a significant arterio-venous difference?

Authors:  Kristin Moksnes; Olav M Fredheim; Pål Klepstad; Stein Kaasa; Anders Angelsen; Turid Nilsen; Ola Dale
Journal:  Eur J Clin Pharmacol       Date:  2008-01-06       Impact factor: 2.953

9.  Intranasal ketamine for procedural sedation in pediatric laceration repair: a preliminary report.

Authors:  Daniel S Tsze; Dale W Steele; Jason T Machan; Fatemeh Akhlaghi; James G Linakis
Journal:  Pediatr Emerg Care       Date:  2012-08       Impact factor: 1.454

10.  Intranasal fentanyl for pain control: current status with a focus on patient considerations.

Authors:  Eric Prommer; Lisa Thompson
Journal:  Patient Prefer Adherence       Date:  2011-03-18       Impact factor: 2.711

View more
  5 in total

Review 1.  Evaluation of Intranasal Midazolam for Pediatric Sedation during the Suturing of Traumatic Lacerations: A Systematic Review.

Authors:  Francisco Javier Gómez-Manzano; José Alberto Laredo-Aguilera; Ana Isabel Cobo-Cuenca; Joseba Rabanales-Sotos; Sergio Rodríguez-Cañamero; Noelia Martín-Espinosa; Juan Manuel Carmona-Torres
Journal:  Children (Basel)       Date:  2022-04-29

Review 2.  Essential pharmacologic options for acute pain management in the emergency setting.

Authors:  David H Cisewski; Sergey M Motov
Journal:  Turk J Emerg Med       Date:  2018-12-10

3.  Comparison of preadministered and coadministered lidocaine for treating pain and distress associated with intranasal midazolam administration in children: A randomized clinical trial.

Authors:  Nicole C O'Connell; Hilary A Woodward; Pamela L Flores-Sanchez; Son H McLaren; Maria Ieni; Kenneth W McKinley; Sripriya T Shen; Peter S Dayan; Daniel S Tsze
Journal:  J Am Coll Emerg Physicians Open       Date:  2020-08-26

Review 4.  Drug delivery to the brain via the nasal route of administration: exploration of key targets and major consideration factors.

Authors:  Seung-Hyun Jeong; Ji-Hun Jang; Yong-Bok Lee
Journal:  J Pharm Investig       Date:  2022-07-24

5.  In vitro activity of cysteamine against SARS-CoV-2 variants.

Authors:  Jess Thoene; Robert F Gavin; Aaron Towne; Lauren Wattay; Maria Grazia Ferrari; Jennifer Navarrete; Ranajit Pal
Journal:  Mol Genet Metab       Date:  2022-09-05       Impact factor: 4.204

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.